Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The prevalence of Hispanic ethnicity, history of diabetes, and high urine albumin levels at baseline were greater among persons with hematuria (Table 1).Demographic and clinical characteristics of participants according to the presence or absence of hematuria at baselineDipstick Positive 1145 (35)Dipstick Negative 2127 (65)Total 3272 (100)Demography Age (years; mean +/− SD)55 +/− 1259+/− 1057+/− 11 Female Sex (n [%])470 (41)935 (44)1405 (43) Racial/ethnic group (n [%]) Non-Hispanic White365 (32)940 (44)1305 (40) Non-Hispanic Black/African American489 (43)930 (44)1419 (43) Hispanic254 (22)204 (10)458 (14) Other37 (3)53 (2)90 (3) ApoL1 recessive genetic model (n [%])a 0 or 1 copy of APOL1 risk variants350 (81)665 (79)1015 (80) 2 copies of APOL1 risk variants80 (19)176 (21)256 (20) Educational attainment (n [%]) Less than high school346 (30)430 (20)776 (24) High school graduate239 (21)426 (20)665 (20) Some college319 (28)607 (29)926 (28) College graduate or higher241 (21)664 (31)905 (28)Anthropometry BMI (kg/m2; mean +/-SD)32+/−832+/− 832+/− 8 BMI (kg/m2; n [%]) < 25207 (18)282 (13)489 (15) 25 to < 30302 (26)625 (29)927 (28) > =30633 (55)1215 (57)1848 (57) Abdominal Circumference (cm; mean +/-SD)105+/− 18106+/− 17106+/− 18 Fat free mass [kg; median (IQR)]61 (50 to 72)59 (49 to 70)60 (50 to 71) Ankle-brachial index< 0.9 (n [%])209 (19)326 (16)535 (17) Systolic Blood P. (mmHg; mean +/-SD)134+/− 24127/− 21129+/− 22 Diabetes638 (56)1014 (48)1652 (50) Hypertension1013 (88)1878 (88)2891 (88) Tobacco use (n [%]) Current smoker189 (17)273 (13)462 (14) More than 100 cigarettes during lifetime638 (56)1180 (55)1818 (56) Cancer (n[%]) Any cancer in the last 5 years68 (6)158 (7)226 (7) Any non-skin cancer in the last 5 years56 (5)107 (5)163 (5) Cardiovascular Disease (n [%]) Congestive Heart Failure111 (10)229 (11)340 (10) Peripheral Vascular Disease103 (9)137 (6)240 (7) Coronary Disease232 (20)514 (24)746 (23) Cerebrovascular Disesase124 (11)215 (10)339 (10) Any Cardiovascular Disease385 (34)753 (35)1138 (35)Renal Function eGFR (ml/min/1.73 m2; mean +/-SD)40+/−1545+/−1644+/− 16 eGFR (ml/min/1.73 m2; n[%]) (CRIC Eq.) < 30329 (29)390 (18)719 (22) 30 to < 40289 (25)507 (24)796 (24) 40 to < 50239 (21)480 (23)719 (22) 50 to < 60167 (15)380 (18)547 (17) > = 60121 (11)370 (17)491 (15)Urinalysis 24H Urine Albumin [g; median (IQR)]0.50 (0.05 to 1.76)0.04 (0.0 to 0.26)0.08 (0.01 to 0.61) 24H Urine Albumin (n[%]) < 30 mg/day211 (19.54)951 (46.66)1162 (37.27) 30 to < 300 mg/day260 (24.07)605 (29.69)865 (27.74) 300 to < 1000 mg/day224 (20.74)286 (14.03)510 (16.36) > = 1000 mg/day385 (35.65)196 (9.62)581 (18.63)Other laboratory markers Hemoglobin (g/dl; mean+/-SD)12.3+/−1.912.6+/−1.712.5+/− 1.8 CalciumT (mg/dl; mean +/-SD)9.2+/−0.59.2+/−0.59.2+/−0.5 Phosphate (mg/dl; mean +/-SD)3.9+/− 0.73.7+/− 0.63.7+/− 0.7 iPTH [pg/ml; median (IQR)]63 (38 to 107)52 (34 to 85)56 (36 to 92) FGF23 [RU/ml; median (IQR)]175 (105 to 284)141 (95 to 224)150 (99 to 249) Vitamin D [ng/ml; median (IQR)]17.6 (10.8 to 27.2)22.9 (14.5 to 34)20.8 (12.8 to 31.7) Glucose [mg/dl; median (IQR)]100 (87 to 133)98 (87 to 123)98 (87 to 127) HbA1C [%; median (IQR)]6.4 (5.6 to 7.9)6.1 (5.6 to 7.2)6.2 (5.6 to 7.4) HOMAb[mmol/L*μU/mL; median (IQR)]4.5 (2.7 to 8.0)4.1 (2.5 to 7.2)4.2 (2.6 to 7.5) Total Cholesterol (mg/dl; mean+/-SD)191+/−53179+/−42183/−46 HDL (mg/dl; mean+/-SD)46+/−1547+/−1547+/−15 LDL (mg/dl; mean+/-SD)107+/−39100+/−34102+/−36 Triglycerides [mg/dl; median (IQR)]138 (94 to 198)127 (88 to 183)130 (91 to 189) Albumin [g/dl; median (IQR)]3.8 (3.4 to 4.1)4.0 (3.7 to 4.3)3.9 (3.6 to 4.2) Uric Acid (mg/dl; mean+/-SD)7.5+/−1.97.5+/−1.97.5+/−1.9 High sensitivity CRP [mg/l; median (IQR)]2.8 (1.1 to 6.7)2.6 (1.1 to 6.6)2.6 (1.1 to 6.6) High sens.Troponin T [pg/mL; median (IQR)]15.7 (7.3 to 34.3)11.9 (6.0 to 21.6)12.9 (6.3 to 24.6) NTproBNP [pg/mL; median (IQR)]204 (81 to 588)142 (58 to 370)162 (66 to 439)Medication (n [%]) ACE/ARB786 (69.3)1492 (70.7)2278 (70.2) Any anti-platelet agent458 (40.4)1038 (49.2)1496 (46.1) cAMP and Ca modifiers83 (7.3)173 (8.2)256 (7.9) Cox-1-inhibitor425 (37.5)968 (45.9)1393 (42.9) Eicosapentaenoic acid0 (0)2 (0.09)2 (0.06) Heparin3 (0.26)0 (0)3 (0.09) Vitamin K antagonist84 (7)113 (5)197 (6)aApol1 recessive genetic model described among a sample of 1271 non-Hispanic black participants. bHOMA: Insulin Resistance Index

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were a racially and ethnically diverse group of adults (21 to 74 years), with moderate CKD.

Source: Abstract.

The Chronic Renal Insufficiency Cohort (CRIC) Study is a multicenter, prospective cohort study which initially enrolled 3939 participants with CKD (eGFR of 20 to 70 ml/min/1.73m2 at baseline).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study

Cohort study · BMC Nephrology · 2018

Original publication title

Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study

Paula F. Orlandi; Naohiko Fujii; Jason Roy; Hsiang-Yu Chen; L. Lee Hamm; James H. Sondheimer; Jiang He; Michael J. Fischer; Hernan Rincon-Choles; Geetha Krishnan; Raymond Townsend; Tariq Shafi; Chi-yuan Hsu; John W. Kusek; John T. Daugirdas; Harold I. Feldman; the CRIC Study InvestigatorsAppelLawrence J.GoAlan S.LashJames P.RaoPanduranga S.RahmanMahboob

© The Author(s). 2018

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In a large adult cohort with CKD, hematuria was associated with a significantly higher risk of CKD progression and death in the first 2 years of follow-up but did not improve risk prediction.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Hematuria is associated with chronic kidney disease (CKD), but has rarely been examined as a risk factor for CKD progression. We explored whether individuals with hematuria had worse outcomes compared to those without hematuria in the CRIC Study.

Source: Background

Abstract: What methods does the paper describe?

Participants were a racially and ethnically diverse group of adults (21 to 74 years), with moderate CKD. Presence of hematuria (positive dipstick) from a single urine sample was the primary predictor. Outcomes included a 50% or greater reduction in eGFR from baseline, ESRD, and death, over a median follow-up of 7.3 years, analyzed using Cox Proportional Hazards models. Net reclassification indices (NRI) and C statistics were calculated to evaluate their predictive performance.

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (10.1186/s12882-018-0951-0) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

Hematuria was observed in 1145 (29%) of a total of 3272 participants at baseline. Individuals with hematuria were more likely to be Hispanic (22% vs. 9.5%, respectively), have diabetes (56% vs. 48%), lower mean eGFR (40.2 vs. 45.3 ml/min/1.73 m2), and higher levels of urinary albumin > 1.0 g/day (36% vs. 10%). In multivariable-adjusted analysis, individuals with hematuria had a greater risk for all outcomes during the first 2 years of follow-up: Halving of eGFR or ESRD (HR Year 1: 1.68, Year 2: 1.36), ESRD (Year 1: 1.71, Year 2: 1.39) and death (Year 1:1.92, Year 2: 1.77), and these associations were attenuated, thereafter.

Based on NRIs and C-statistics, no clear improvement in the ability to improve prediction of study outcomes was observed when hematuria was included in multivariable models.

Source: Results

Abstract: Conclusion

In a large adult cohort with CKD, hematuria was associated with a significantly higher risk of CKD progression and death in the first 2 years of follow-up but did not improve risk prediction.

Source: Conclusion
Authors’ abstract

Background

Hematuria is associated with chronic kidney disease (CKD), but has rarely been examined as a risk factor for CKD progression. We explored whether individuals with hematuria had worse outcomes compared to those without hematuria in the CRIC Study.

Methods

Participants were a racially and ethnically diverse group of adults (21 to 74 years), with moderate CKD. Presence of hematuria (positive dipstick) from a single urine sample was the primary predictor. Outcomes included a 50% or greater reduction in eGFR from baseline, ESRD, and death, over a median follow-up of 7.3 years, analyzed using Cox Proportional Hazards models. Net reclassification indices (NRI) and C statistics were calculated to evaluate their predictive performance.

Results

Hematuria was observed in 1145 (29%) of a total of 3272 participants at baseline. Individuals with hematuria were more likely to be Hispanic (22% vs. 9.5%, respectively), have diabetes (56% vs. 48%), lower mean eGFR (40.2 vs. 45.3 ml/min/1.73 m2), and higher levels of urinary albumin > 1.0 g/day (36% vs. 10%). In multivariable-adjusted analysis, individuals with hematuria had a greater risk for all outcomes during the first 2 years of follow-up: Halving of eGFR or ESRD (HR Year 1: 1.68, Year 2: 1.36), ESRD (Year 1: 1.71, Year 2: 1.39) and death (Year 1:1.92, Year 2: 1.77), and these associations were attenuated, thereafter.

Based on NRIs and C-statistics, no clear improvement in the ability to improve prediction of study outcomes was observed when hematuria was included in multivariable models.

Conclusion

In a large adult cohort with CKD, hematuria was associated with a significantly higher risk of CKD progression and death in the first 2 years of follow-up but did not improve risk prediction.

Electronic supplementary material

The online version of this article (10.1186/s12882-018-0951-0) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study

Paula F. Orlandi; Naohiko Fujii; Jason Roy; Hsiang-Yu Chen; L. Lee Hamm; James H. Sondheimer; Jiang He; Michael J. Fischer; Hernan Rincon-Choles; Geetha Krishnan; Raymond Townsend; Tariq Shafi; Chi-yuan Hsu; John W. Kusek; John T. Daugirdas; Harold I. Feldman; the CRIC Study InvestigatorsAppelLawrence J.GoAlan S.LashJames P.RaoPanduranga S.RahmanMahboob

BMC Nephrology · 2018

© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.NIDDKU01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902http://dx.doi.org/10.13039/100007928Perelman School of Medicine, University of PennsylvaniaUL1TR000003http://dx.doi.org/10.13039/100007880Johns Hopkins UniversityUL1TR000424http://dx.doi.org/10.13039/100001365University of Maryland FoundationGCRC M01RR-16500Clinical and Translational Collaborative of ClevelandUL1TR000439http://dx.doi.org/10.13039/100006108National Center for Advancing Translational SciencesUL1TR000433http://dx.doi.org/10.13039/100007234University of ChicagoUL1RR029879http://dx.doi.org/10.13039/100007875Tulane UniversityGM109036,http://dx.doi.org/10.13039/100005977Kaiser PermanenteUL1 RR-024131

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:05:49.314313+00:00

DOI: 10.1186/s12882-018-0951-0 · PMC6020240